MedTrace Logo

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

NCT00726687 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2012-07-19

No results posted yet for this study

Summary

This is a phase 1b study of Indibulin in combination with Capecitabine in advanced solid tumors.

Conditions

Interventions

DRUG

indibulin

indibulin, dose escalation, 400-600 mg taken twice every day

DRUG

capecitabine

capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jonathan Lewis, MD · Alaunos Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726687 on ClinicalTrials.gov